Is it Apt to Retain HAE Stock in Your Portfolio for Now?

Haemonetics Corporation’s (HAE) impressive Hospital business recovery is poised to drive growth in the upcoming quarters. The robust uptake of the NexSys PCS system bodes well for its long-term growth. Strong financial stability also buoys optimism. Meanwhile, a dull macroeconomic scenario and unfavorable foreign exchange remain concerns for HAE’s operations. In the past year, this Zacks Rank #3 (Hold) company’s shares have lost 14.5% against the industry and the S&P 500 composite’s growth of 9% and 10%, re ...